Oral Medication Approved for MS in Canada

.

Oral Medication Approved for MS in Canada

Multiple Sclerosis treatment is bound to revolutionize in Canada as drug-maker Novartis Pharmaceutical Canada Inc. announced on Thursday that the first oral medicine for the condition has been approved for use by some patients in the country. The medication will basically help in providing treatment for the symptoms of MS.

The medicine has been named Gilenya and will be available for sale from the 1st of April at pharmaceutical stores across the nation. The medicine will be available for people who have tried another treatment for the condition with poor results.

The chemical name for Gilenya is fingolimod and it will be used for people with the relapsing-remitting form of the condition. According to the figures available, the disease ends up affecting an astounding 75,000 Canadians. People with this variety of the condition are likely to experience new symptoms with severity of older symptoms worsening.

Gilenya will help in reducing flare-ups of people suffering from multiple sclerosis and will also help in reducing the rate of progress. Each capsule of Gilenya contains 0.5 milligrams of the drug and is the most convenient treatment for MS in Canada.

Talking about the development, a Neurologist from Toronto, Dr. Daniel Selchan, said: "The approval of Gilenya is a significant milestone for the Canadian MS community".


Latest News

Virginia police refused service at Noodles & Co due to cop animosity
Town’s Mayor offers $100 reward for catching Alligator Gar
Young boy’s Prosthetic Leg stolen in Orange County on Sunday
Charges dropped against three officials in Freddie Gray case
Uber and Didi
CBS Corp Posts Better than Expected Quarterly Earnings Boosted Partly by “Star T
Google’s Parent Alphabet Inc. Report Quarterly Results beyond Analysts’ Expectat
Amazon Reports Record Profits for the Second Consecutive Quarter
Reagan shooter to be released from a Washington psychiatric hospital
Trump Claims He has No Interest in Russia
Facebook’s Second Quarter Earnings Beat Expectations; Share Prices Soar
Fed Signals Gradual Rate Hike; Asian Currencies Won and Ringgit Gain on Weaker D